Select is a landmark trial and has demonstrated that semaglutide 2.4mg has the potential to change how obesity is regarded and treated. Professor Stephen ORahilly, director of the MRC Metabolic Diseases Unit at the Institute of Metabolic Science, University of Cambridge, said the results have been long awaited and do not disappoint
Midlife adults often want better focus and mood, especially when long workdays meet changing sleep patterns
Cuthbertson DJ, Irwin A, Gardner CJ et al (2012) Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists
Katsurada K, Yada T
And as of recently, an enthusiastic GLP-1 user
Although human safety data is limited, preclinical studies indicate BPC 157 is generally well-tolerated in laboratory models